Buprenorphine Subcutaneous Injection
A new buprenorphine prolonged-release injection administered under the skin, either weekly or monthly, is available to our patients.
No need for daily or weekly pick up from your chemist nor supervised consumption.
Buvidal (buprenorphine prolonged-release solution for subcutaneous injection in prefilled syringe) has been developed for the treatment of opioid dependence (heroin, morphine, painkiller addiction) within a framework of medical, social and psychological treatment.
Buvidal is designed for flexible dosing and is available in different weekly and monthly strengths, enabling treatment to be tailored to the patient's individual needs.
Click for more information about Buvidal on NICE and European Medicines Agency websites.
Current established buprenorphine medications, which are the most frequently used treatment for opioid dependence globally, are taken every day as a sublingual tablet or film. However, this form of administration has a number of drawbacks – including frequent visits to the chemist, need for supervised consumption, complicated travel arrangements, and accidental ingestion by children.
The way Buvidal functions is dependent on ’FluidCrystal' injection depot using cutting edge technology, which aims to improve therapeutic performance, treatment adherence and clinical outcomes – and ultimately the patient’s quality of life. Designed as a versatile drug delivery technology, FluidCrystal is used to create convenient, long-acting treatments.
Click here to access 3 cases studies published Case Reports in Psychiatry 2019 by our medical director.
Buvidal treatment is now available to The OAD Clinic patients.